Immune memory may cause recurring arthritis during cancer immunotherapy

When arthritis develops during cancer immunotherapy, swollen hands can make it hard to open a jar or turn a doorknob. Inflammation in the knees can make walking difficult. For some patients, the joint pain and swelling ease, only to return.

These subsequent flares can be severe enough to interrupt cancer immunotherapy, according to Sang Taek Kim, MD, PhD, assistant professor of medicine (rheumatology, allergy & immunology) at Yale School of Medicine, who notes that approximately 20% to 25% of cancer patients will have rheumatological adverse events after receiving immunotherapy. To better understand why the inflammation recurs, he and his colleagues examined what changed inside the joints between initial and subsequent flares.

In their study, published in Cancer Immunology Research, the team found that some groups of immune cells present during the first flare had become numerous by the second flare. The pattern suggests that during the second occurrence of inflammatory arthritis, the immune system may be drawing on its memory of the earlier response.

"When our immune system encounters the same antigens, those responses can get stronger," explains Kim, who directs the Yale Immunotherapy Adverse Events in Rheumatology Program.

The researchers focused on patients who had received immune checkpoint inhibitors, a type of cancer immunotherapy drug that removes some of the restraints on T cells, allowing them to attack tumors more effectively. In some patients, the immune response also inflames healthy tissues, including the joints.

The team compared joint fluid collected from patients during their first and second episodes of arthritis. The researchers used single-cell sequencing, T-cell receptor sequencing, and flow cytometry to examine which genes were active in individual cells and to track groups of T cells that mediated joint inflammation.

"We noticed the PD-1hi CXCL13hi CD4+T cells and effector CD8+T cells from the first flare grew in number by the second flare," Kim says. The findings suggest that these cells may drive inflammation in the joints and play a role in recurrence.

Our next step is to find out what triggers this recurrence."

Sang Taek Kim, MD, PhD, assistant professor of medicine, Yale School of Medicine

Kim plans to investigate whether these T cells identified in the joints can also be found in blood. If larger studies show that the cells can signal a second flare before symptoms begin, a blood test could help doctors identify patients whose arthritis is more likely to return.

The team also wants to learn whether the cells involved in joint inflammation differ from those that help fight cancer. "Our goal is to make sure patients can continue treatment without interruption by helping develop therapies that ease joint inflammation while preserving the immune system's ability to fight cancer," he says.

Rheumatology, Allergy & Immunology, one of 10 sections in the Yale Department of Internal Medicine, is dedicated to providing care for patients with rheumatic, allergic, and immunologic disorders; educating future generations of thought leaders in the field; and researching fundamental questions of autoimmunity and immunology. To learn more, visit Rheumatology, Allergy & Immunology.

Source:
Journal reference:

Keam, S., et al. (2026). Immune hallmarks of recurrent immune checkpoint inhibitor–mediated inflammatory arthritis. Cancer Immunology Research. DOI: 10.1158/2326-6066.CIR-25-1639. https://aacrjournals.org/cancerimmunolres/article-abstract/14/10/1653/788592/Immune-Hallmarks-of-Recurrent-Immune-Checkpoint

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DNA damage in T cells limits effectiveness of immunotherapies